Sunitinib is an orally taken multi-target receptor tyrosine kinase inhibitor that can reverse immune suppression, making it a prospective adjuvant to improve the efficacy of immunotherapy in advanced cancers (110). The gene discussed is NTRK1; the disease is cancer.